دورية أكاديمية

MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT.

التفاصيل البيبلوغرافية
العنوان: MCTP1 increases the malignancy of androgen-deprived prostate cancer cells by inducing neuroendocrine differentiation and EMT.
المؤلفون: Liu, Yen-Nien, Chen, Wei-Yu, Yeh, Hsiu-Lien, Chen, Wei-Hao, Jiang, Kuo-Ching, Li, Han-Ru, Dung, Phan Vu Thuy, Chen, Zi-Qing, Lee, Wei-Jiunn, Hsiao, Michael, Huang, Jiaoti, Wen, Yu-Ching
المصدر: Science Signaling; 6/11/2024, Vol. 17 Issue 840, p1-18, 18p
مصطلحات موضوعية: PROSTATE cancer, NEUROENDOCRINE cells, CANCER cells, ANDROGEN deprivation therapy, CANCER cell migration, ANDROGEN receptors
مستخلص: Neuroendocrine prostate cancer (PCa) (NEPC), an aggressive subtype that is associated with poor prognosis, may arise after androgen deprivation therapy (ADT). We investigated the molecular mechanisms by which ADT induces neuroendocrine differentiation in advanced PCa. We found that transmembrane protein 1 (MCTP1), which has putative Ca2+ sensing function and multiple Ca2+-binding C2 domains, was abundant in samples from patients with advanced PCa. MCTP1 was associated with the expression of the EMT-associated transcription factors ZBTB46, FOXA2, and HIF1A. The increased abundance of MCTP1 promoted PC3 prostate cancer cell migration and neuroendocrine differentiation and was associated with SNAI1-dependent EMT in C4-2 PCa cells after ADT. ZBTB46 interacted with FOXA2 and HIF1A and increased the abundance of MCTP1 in a hypoxia-dependent manner. MCTP1 stimulated Ca2+ signaling and AKT activation to promote EMT and neuroendocrine differentiation by increasing the SNAI1-dependent expression of EMT and neuroendocrine markers, effects that were blocked by knockdown of MCTP1. These data suggest an oncogenic role for MCTP1 in the maintenance of a rare and aggressive prostate cancer subtype through its response to Ca2+ and suggest its potential as a therapeutic target. Editor's summary: Androgen deprivation therapy is used to treat prostate cancer but can induce its differentiation into an aggressive neuroendocrine subtype with poor clinical outcomes. Liu et al. uncovered a role for the putative Ca2+ sensor MCTP1 in neuroendocrine differentiation in prostate cancer. MCTP1 was abundant in human prostate tumors, and its expression in prostate cancer cells was stimulated by the transcription factors ZBTB46, FOXA2, and HIF1A in a hypoxia-dependent manner. MCTP1 expression promoted tumor progression and epithelial-to-mesenchymal transition, thus suggesting that targeting MCTP1 could prevent neuroendocrine differentiation in prostate cancer. —Amy E. Baek [ABSTRACT FROM AUTHOR]
Copyright of Science Signaling is the property of American Association for the Advancement of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:19450877
DOI:10.1126/scisignal.adc9142